| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | protein serine/threonine kinase activity | 9.70e-03 | 446 | 7 | 2 | GO:0004674 | |
| GeneOntologyBiologicalProcess | in utero embryonic development | 2.25e-05 | 596 | 7 | 4 | GO:0001701 | |
| GeneOntologyBiologicalProcess | chordate embryonic development | 1.16e-04 | 906 | 7 | 4 | GO:0043009 | |
| GeneOntologyBiologicalProcess | embryo development ending in birth or egg hatching | 1.28e-04 | 929 | 7 | 4 | GO:0009792 | |
| GeneOntologyBiologicalProcess | embryo development | 6.92e-04 | 1437 | 7 | 4 | GO:0009790 | |
| GeneOntologyBiologicalProcess | regulation of mRNA processing | 1.19e-03 | 158 | 7 | 2 | GO:0050684 | |
| GeneOntologyCellularComponent | nuclear body | 1.09e-04 | 903 | 7 | 4 | GO:0016604 | |
| GeneOntologyCellularComponent | nuclear speck | 2.86e-04 | 431 | 7 | 3 | GO:0016607 | |
| MousePheno | abnormal optic cup morphology | 1.31e-04 | 42 | 6 | 2 | MP:0004269 | |
| MousePheno | fusion of vertebral arches | 2.78e-04 | 61 | 6 | 2 | MP:0004613 | |
| MousePheno | abnormal vein development | 3.66e-04 | 70 | 6 | 2 | MP:0003411 | |
| MousePheno | abnormal basicranium morphology | 1.13e-03 | 123 | 6 | 2 | MP:0010029 | |
| MousePheno | vertebral fusion | 1.97e-03 | 163 | 6 | 2 | MP:0004609 | |
| MousePheno | fused joints | 2.14e-03 | 170 | 6 | 2 | MP:0003189 | |
| MousePheno | abnormal pharyngeal arch morphology | 2.16e-03 | 171 | 6 | 2 | MP:0002884 | |
| MousePheno | abnormal vertebral arch morphology | 2.24e-03 | 174 | 6 | 2 | MP:0004599 | |
| MousePheno | abnormal vein morphology | 2.29e-03 | 176 | 6 | 2 | MP:0002725 | |
| MousePheno | embryonic lethality before implantation, complete penetrance | 3.03e-03 | 203 | 6 | 2 | MP:0011094 | |
| MousePheno | embryonic lethality before implantation | 4.28e-03 | 242 | 6 | 2 | MP:0006204 | |
| MousePheno | abnormal neurocranium morphology | 5.26e-03 | 269 | 6 | 2 | MP:0000074 | |
| Pathway | REACTOME_RNA_POLYMERASE_II_TRANSCRIPTION | 8.16e-03 | 1387 | 5 | 3 | M734 | |
| Pathway | REACTOME_GENERIC_TRANSCRIPTION_PATHWAY | 2.66e-02 | 768 | 5 | 2 | MM14851 | |
| Pubmed | ATG5 is required for B cell polarization and presentation of particulate antigens. | 5.46e-06 | 701 | 7 | 4 | 30196744 | |
| Pubmed | 1.27e-05 | 251 | 7 | 3 | 28077445 | ||
| Pubmed | SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis through NSP9. | 1.38e-05 | 258 | 7 | 3 | 37794589 | |
| Pubmed | 5.22e-05 | 403 | 7 | 3 | 35253629 | ||
| Pubmed | 1.95e-04 | 107 | 7 | 2 | 11347906 | ||
| Interaction | LINC02910 interactions | 3.50e-06 | 95 | 7 | 3 | int:LINC02910 | |
| Interaction | PNMA2 interactions | 6.44e-05 | 251 | 7 | 3 | int:PNMA2 | |
| Interaction | HNRNPA1 interactions | 1.50e-04 | 945 | 7 | 4 | int:HNRNPA1 | |
| Interaction | PYHIN1 interactions | 1.85e-04 | 358 | 7 | 3 | int:PYHIN1 | |
| Interaction | PSENEN interactions | 3.31e-04 | 81 | 7 | 2 | int:PSENEN | |
| Interaction | ATG16L1 interactions | 3.33e-04 | 1161 | 7 | 4 | int:ATG16L1 | |
| Interaction | DDX23 interactions | 4.38e-04 | 480 | 7 | 3 | int:DDX23 | |
| Interaction | NUAK1 interactions | 4.64e-04 | 96 | 7 | 2 | int:NUAK1 | |
| Interaction | GLI3 interactions | 4.84e-04 | 98 | 7 | 2 | int:GLI3 | |
| Interaction | ANKHD1-EIF4EBP3 interactions | 5.87e-04 | 108 | 7 | 2 | int:ANKHD1-EIF4EBP3 | |
| Interaction | ANKRD50 interactions | 5.87e-04 | 108 | 7 | 2 | int:ANKRD50 | |
| Interaction | FMR1 interactions | 6.05e-04 | 536 | 7 | 3 | int:FMR1 | |
| Interaction | E2F4 interactions | 6.18e-04 | 540 | 7 | 3 | int:E2F4 | |
| Interaction | TBCB interactions | 6.54e-04 | 114 | 7 | 2 | int:TBCB | |
| Interaction | SOX2 interactions | 7.27e-04 | 1422 | 7 | 4 | int:SOX2 | |
| Interaction | HSF1 interactions | 8.78e-04 | 609 | 7 | 3 | int:HSF1 | |
| Interaction | PABPC5 interactions | 1.01e-03 | 142 | 7 | 2 | int:PABPC5 | |
| Interaction | APOBEC3D interactions | 1.10e-03 | 148 | 7 | 2 | int:APOBEC3D | |
| Interaction | BMI1 interactions | 1.10e-03 | 659 | 7 | 3 | int:BMI1 | |
| Interaction | INTS5 interactions | 1.25e-03 | 158 | 7 | 2 | int:INTS5 | |
| Interaction | CEP85 interactions | 1.43e-03 | 169 | 7 | 2 | int:CEP85 | |
| Interaction | ALG13 interactions | 1.67e-03 | 183 | 7 | 2 | int:ALG13 | |
| Interaction | ELAVL2 interactions | 1.76e-03 | 188 | 7 | 2 | int:ELAVL2 | |
| Interaction | DOT1L interactions | 1.98e-03 | 807 | 7 | 3 | int:DOT1L | |
| Interaction | RBM47 interactions | 2.07e-03 | 204 | 7 | 2 | int:RBM47 | |
| Interaction | ZC3H11A interactions | 2.30e-03 | 215 | 7 | 2 | int:ZC3H11A | |
| Interaction | CLK3 interactions | 2.40e-03 | 220 | 7 | 2 | int:CLK3 | |
| Interaction | ANKRD17 interactions | 2.53e-03 | 226 | 7 | 2 | int:ANKRD17 | |
| Interaction | ANKRD28 interactions | 2.74e-03 | 235 | 7 | 2 | int:ANKRD28 | |
| Interaction | OTUD4 interactions | 2.76e-03 | 236 | 7 | 2 | int:OTUD4 | |
| Interaction | EYA4 interactions | 2.92e-03 | 243 | 7 | 2 | int:EYA4 | |
| Interaction | EIF3D interactions | 2.95e-03 | 244 | 7 | 2 | int:EIF3D | |
| Interaction | TAF1 interactions | 3.34e-03 | 260 | 7 | 2 | int:TAF1 | |
| Interaction | RNF40 interactions | 3.36e-03 | 261 | 7 | 2 | int:RNF40 | |
| Interaction | NAA40 interactions | 3.44e-03 | 978 | 7 | 3 | int:NAA40 | |
| Interaction | PRRC2B interactions | 3.46e-03 | 265 | 7 | 2 | int:PRRC2B | |
| Interaction | SNRNP70 interactions | 3.50e-03 | 984 | 7 | 3 | int:SNRNP70 | |
| Interaction | AR interactions | 3.58e-03 | 992 | 7 | 3 | int:AR | |
| Interaction | LEO1 interactions | 3.80e-03 | 278 | 7 | 2 | int:LEO1 | |
| Interaction | TNRC6A interactions | 3.86e-03 | 280 | 7 | 2 | int:TNRC6A | |
| Interaction | DVL3 interactions | 3.86e-03 | 280 | 7 | 2 | int:DVL3 | |
| Interaction | TNRC6B interactions | 3.91e-03 | 282 | 7 | 2 | int:TNRC6B | |
| Interaction | MEN1 interactions | 3.98e-03 | 1029 | 7 | 3 | int:MEN1 | |
| Interaction | HNRNPUL2 interactions | 4.16e-03 | 291 | 7 | 2 | int:HNRNPUL2 | |
| Interaction | SRSF4 interactions | 4.41e-03 | 300 | 7 | 2 | int:SRSF4 | |
| Interaction | EIF4ENIF1 interactions | 4.41e-03 | 300 | 7 | 2 | int:EIF4ENIF1 | |
| Interaction | YTHDF1 interactions | 4.47e-03 | 302 | 7 | 2 | int:YTHDF1 | |
| Interaction | BCOR interactions | 4.47e-03 | 302 | 7 | 2 | int:BCOR | |
| Interaction | SAP18 interactions | 4.56e-03 | 305 | 7 | 2 | int:SAP18 | |
| Interaction | CNOT1 interactions | 4.56e-03 | 305 | 7 | 2 | int:CNOT1 | |
| Interaction | YTHDF2 interactions | 4.77e-03 | 312 | 7 | 2 | int:YTHDF2 | |
| Coexpression | GSE29617_CTRL_VS_DAY3_TIV_FLU_VACCINE_PBMC_2008_UP | 1.41e-05 | 196 | 7 | 3 | M4928 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial-Astro-Astrocyte-Astro_L1_FGFR3_MT1G|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.52e-04 | 186 | 7 | 2 | 41e03be964044dae690d566bd078dab3d8045eba | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial-Astro-Astrocyte|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.56e-04 | 187 | 7 | 2 | 5c73010fe4c85fb5cc1273f5504821229ca0cc4b | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial-Astro|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.56e-04 | 187 | 7 | 2 | 5d3d68519c8e19f10c29f9d81712125be78ca15a | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.60e-04 | 188 | 7 | 2 | 505b6b4277d7dea87aee27191d0acca67928b8e6 | |
| ToppCell | primary_auditory_cortex_(A1C)-Non-neuronal-Macroglial|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.64e-04 | 189 | 7 | 2 | 784ace2be87f2ecb19490f4974f63a559516e0eb | |
| ToppCell | primary_auditory_cortex_(A1C)-Non-neuronal|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.64e-04 | 189 | 7 | 2 | 37ecbd73408d462b47d7e5611f203143e08a2689 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Non-neuronal-Macroglial-Astro|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.67e-04 | 190 | 7 | 2 | 78cc6c28b31de041c24175a98f47da256ecc15a2 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Non-neuronal-Macroglial-Astro-Astrocyte|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.67e-04 | 190 | 7 | 2 | e67d9400467b438592690b23d681e6c2fb8f09fd | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Non-neuronal-Macroglial|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.67e-04 | 190 | 7 | 2 | 2de8e4cfeee350a9a76af749d6ce58d948c129b8 | |
| ToppCell | Somatosensory_Cortex_(S1)-Non-neuronal-Macroglial|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.67e-04 | 190 | 7 | 2 | 07f21386ea6eb23416a537d2250e3042efe93fb0 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Non-neuronal|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.71e-04 | 191 | 7 | 2 | a90c8ab2077e52bbc998457c85a1b9867f9c8c93 | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Non-neuronal|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.71e-04 | 191 | 7 | 2 | f3158cedf67e3b90aa94ea1f61c72c33aaa2d5ba | |
| ToppCell | LA|World / Chamber and Cluster_Paper | 3.79e-04 | 193 | 7 | 2 | d4bf89437216baf489ea0239136dcedf3b6714af | |
| ToppCell | droplet-Lung-30m-Mesenchymal-fibroblast-adventitial_fibroblast|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 3.79e-04 | 193 | 7 | 2 | 9d0b966d13cbce97beb43de6dc77f006c363a181 | |
| ToppCell | PCW_05-06-Mesenchymal|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 3.91e-04 | 196 | 7 | 2 | dca52c57ba35d9395cdbca8b881f12ece721b10f | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 3.91e-04 | 196 | 7 | 2 | 1450cb69c5bf469e97c03bf1890f6f7c54165b8a | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature3_(17)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 3.95e-04 | 197 | 7 | 2 | 31a1852911bda38543916585fda34255fd62a134 | |
| ToppCell | H1299-infected-SARSCoV2|infected / Cell line, Condition and Strain | 3.95e-04 | 197 | 7 | 2 | 0fa3e4cf93e77d78b1f97b906c5b13ca741ae17e | |
| ToppCell | PCW_13-14-Mesenchymal|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 3.95e-04 | 197 | 7 | 2 | 73a2085d2682d636726a5432d572ae2a3fbe1c3f | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 3.99e-04 | 198 | 7 | 2 | 17dc055e2a289496d9c5cdbf3297bdf906dc6d22 | |
| ToppCell | Macroglial|World / cells hierarchy compared to all cells using T-Statistic | 4.07e-04 | 200 | 7 | 2 | e6935ad49216d2500c15c05cbc2b89402c65e838 | |
| Computational | Neighborhood of UBE2N | 1.20e-03 | 154 | 4 | 2 | GCM_UBE2N | |
| Drug | Cephalosporanic acid, 7-amino [957-68-6]; Down 200; 14.6uM; MCF7; HT_HG-U133A | 2.14e-05 | 196 | 7 | 3 | 4826_DN | |
| Drug | Leflunomide [75706-12-6]; Down 200; 14.8uM; PC3; HT_HG-U133A | 2.18e-05 | 197 | 7 | 3 | 5884_DN | |
| Drug | felodipine; Up 200; 10uM; MCF7; HT_HG-U133A_EA | 1.30e-03 | 182 | 7 | 2 | 848_UP | |
| Drug | Labetalol hydrochloride [32780-64-6]; Up 200; 11uM; HL60; HG-U133A | 1.42e-03 | 190 | 7 | 2 | 1550_UP | |
| Drug | Promazine hydrochloride [53-60-1]; Down 200; 12.4uM; MCF7; HT_HG-U133A | 1.42e-03 | 190 | 7 | 2 | 3927_DN | |
| Drug | 5707885; Down 200; 50uM; PC3; HT_HG-U133A | 1.43e-03 | 191 | 7 | 2 | 6390_DN | |
| Drug | Econazole nitrate [24169-02-6]; Down 200; 9uM; MCF7; HT_HG-U133A | 1.44e-03 | 192 | 7 | 2 | 7427_DN | |
| Drug | pioglitazone HCl; Up 200; 10uM; MCF7; HT_HG-U133A | 1.47e-03 | 194 | 7 | 2 | 7523_UP | |
| Drug | Mebeverine hydrochloride [2753-45-9]; Down 200; 8.6uM; MCF7; HT_HG-U133A | 1.47e-03 | 194 | 7 | 2 | 3193_DN | |
| Drug | Clotrimazole [23593-75-1]; Down 200; 11.6uM; MCF7; HT_HG-U133A | 1.47e-03 | 194 | 7 | 2 | 3166_DN | |
| Drug | Altretamine [654-05-6]; Down 200; 19uM; MCF7; HT_HG-U133A | 1.47e-03 | 194 | 7 | 2 | 6467_DN | |
| Drug | novobiocin sodium, USP; Down 200; 100uM; SKMEL5; HG-U133A | 1.49e-03 | 195 | 7 | 2 | 632_DN | |
| Drug | Homocysteine | 1.49e-03 | 195 | 7 | 2 | ctd:D006710 | |
| Drug | Cefsulodin sodium salt [52152-93-9]; Down 200; 7.2uM; MCF7; HT_HG-U133A | 1.49e-03 | 195 | 7 | 2 | 3328_DN | |
| Drug | wortmannin from Penicillium funiculosum; Down 200; 0.01uM; PC3; HT_HG-U133A | 1.49e-03 | 195 | 7 | 2 | 1243_DN | |
| Drug | Testosterone propionate [57-85-2]; Down 200; 11.6uM; MCF7; HT_HG-U133A | 1.49e-03 | 195 | 7 | 2 | 2649_DN | |
| Drug | Nicergoline; Down 200; 8.2uM; PC3; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 2058_DN | |
| Drug | Acetazolamide [59-66-5]; Down 200; 18uM; MCF7; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 1686_DN | |
| Drug | Ivermectin [70288-86-7]; Down 200; 4.6uM; PC3; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 2051_DN | |
| Drug | Etofenamate [30544-47-9]; Down 200; 10.8uM; HL60; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 2907_DN | |
| Drug | Chrysin [480-40-0]; Down 200; 15.8uM; MCF7; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 5505_DN | |
| Drug | retinoic acid; Up 200; 1uM; MCF7; HG-U133A | 1.50e-03 | 196 | 7 | 2 | 384_UP | |
| Drug | Sulfadoxine [2447-57-6]; Down 200; 12.8uM; MCF7; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 3547_DN | |
| Drug | Pirenzepine dihydrochloride [29868-97-1]; Down 200; 9.4uM; MCF7; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 7226_DN | |
| Drug | Testosterone propionate [57-85-2]; Down 200; 11.6uM; MCF7; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 5636_DN | |
| Drug | Nalbuphine hydrochloride [23277-43-2]; Up 200; 10.2uM; HL60; HG-U133A | 1.50e-03 | 196 | 7 | 2 | 1379_UP | |
| Drug | Nalbuphine hydrochloride [23277-43-2]; Down 200; 10.2uM; MCF7; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 2225_DN | |
| Drug | Triamterene [396-01-0]; Down 200; 15.8uM; PC3; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 1819_DN | |
| Drug | Mifepristone [84371-65-3]; Down 200; 9.4uM; MCF7; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 7183_DN | |
| Drug | Pyrimethamine [58-14-0]; Up 200; 16uM; PC3; HG-U133A | 1.50e-03 | 196 | 7 | 2 | 1894_UP | |
| Drug | Methoxy-8-psoralen [298-81-7]; Down 200; 18.6uM; MCF7; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 3302_DN | |
| Drug | Carbarsone [121-59-5]; Down 200; 15.4uM; MCF7; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 3250_DN | |
| Drug | Piroxicam [36322-90-4]; Up 200; 12uM; MCF7; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 2252_UP | |
| Drug | Boldine [476-70-0]; Down 200; 12.2uM; HL60; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 2148_DN | |
| Drug | Clindamycin hydrochloride [21462-39-5]; Down 200; 8.6uM; PC3; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 5815_DN | |
| Drug | Fludrocortisone acetate [514-36-3]; Down 200; 9.4uM; MCF7; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 2328_DN | |
| Drug | rapamycin; Down 200; 0.1uM; HL60; HG-U133A | 1.52e-03 | 197 | 7 | 2 | 362_DN | |
| Drug | (+,-)-Synephrine [94-07-5]; Up 200; 24uM; MCF7; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 6798_UP | |
| Drug | Ajmaline [4360-12-7]; Down 200; 12.2uM; MCF7; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 2899_DN | |
| Drug | Aconitine [302-27-2]; Up 200; 6.2uM; MCF7; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 6797_UP | |
| Drug | Bepridil hydrochloride [74764-40-2]; Down 200; 10uM; MCF7; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 2629_DN | |
| Drug | Fendiline hydrochloride [13636-18-5]; Down 200; 11.4uM; HL60; HG-U133A | 1.52e-03 | 197 | 7 | 2 | 1573_DN | |
| Drug | radicicol; Down 200; 0.1uM; PC3; HG-U133A | 1.52e-03 | 197 | 7 | 2 | 449_DN | |
| Drug | clozapine; Down 200; 10uM; MCF7; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 5589_DN | |
| Drug | Suramin sodium salt; Up 200; 10uM; MCF7; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 7524_UP | |
| Drug | Proadifen hydrochloride [62-68-0]; Down 200; 10.2uM; PC3; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 5807_DN | |
| Drug | haloperidol; Up 200; 10uM; HL60; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 6163_UP | |
| Drug | 2-propylpentanoic acid; Down 200; 50uM; MCF7; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 5582_DN | |
| Drug | Dioxybenzone [131-53-3]; Down 200; 16.4uM; MCF7; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 5699_DN | |
| Drug | Chlorzoxazone [95-25-0]; Down 200; 23.6uM; PC3; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 2100_DN | |
| Drug | Pinacidil [85371-64-8]; Up 200; 16.4uM; PC3; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 6356_UP | |
| Drug | clozapine; Down 200; 10uM; HL60; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 1170_DN | |
| Drug | Pralidoxime chloride [51-15-0]; Down 200; 23.2uM; MCF7; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 5383_DN | |
| Drug | Lynestrenol [52-76-6]; Down 200; 14uM; MCF7; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 1537_DN | |
| Drug | Cisapride [81098-60-4]; Down 200; 8.6uM; MCF7; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 3305_DN | |
| Drug | genistein; Up 200; 10uM; MCF7; HG-U133A | 1.54e-03 | 198 | 7 | 2 | 382_UP | |
| Drug | Buflomedil hydrochloride [35543-24-9]; Down 200; 11.6uM; PC3; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 4258_DN | |
| Drug | ICI 182,780; Up 200; 0.01uM; HL60; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 6197_UP | |
| Drug | Pyrilamine maleate [59-33-6]; Down 200; 10uM; PC3; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 5869_DN | |
| Drug | Naloxone hydrochloride [357-08-4]; Up 200; 11uM; PC3; HG-U133A | 1.54e-03 | 198 | 7 | 2 | 1924_UP | |
| Drug | Doxylamine succinate [562-10-7]; Up 200; 10.2uM; PC3; HG-U133A | 1.55e-03 | 199 | 7 | 2 | 1893_UP | |
| Drug | Ganciclovir [82410-32-0]; Up 200; 15.6uM; MCF7; HT_HG-U133A | 1.55e-03 | 199 | 7 | 2 | 5389_UP | |
| Drug | Hydroxyzine dihydrochloride [2192-20-3]; Down 200; 9uM; MCF7; HT_HG-U133A | 1.55e-03 | 199 | 7 | 2 | 5006_DN | |
| Drug | PF-01378883-00 [351320-41-7]; Up 200; 10uM; PC3; HT_HG-U133A | 1.55e-03 | 199 | 7 | 2 | 6410_UP | |
| Drug | Bumetanide [28395-03-1]; Down 200; 11uM; MCF7; HT_HG-U133A | 1.55e-03 | 199 | 7 | 2 | 5542_DN | |
| Drug | Flufenamic acid [530-78-9]; Down 200; 14.2uM; MCF7; HT_HG-U133A | 1.55e-03 | 199 | 7 | 2 | 5478_DN | |
| Drug | Pentamidine isethionate [140-64-7]; Up 200; 6.8uM; MCF7; HT_HG-U133A | 1.55e-03 | 199 | 7 | 2 | 2834_UP | |
| Drug | Yohimbinic acid monohydrate [27801-27-2]; Down 200; 11.2uM; MCF7; HT_HG-U133A | 1.55e-03 | 199 | 7 | 2 | 2803_DN | |
| Drug | Mafenide hydrochloride [138-37-4]; Down 200; 18uM; MCF7; HT_HG-U133A | 1.55e-03 | 199 | 7 | 2 | 2287_DN | |
| Drug | Cephapirin sodium salt [24356-60-3]; Up 200; 9uM; MCF7; HT_HG-U133A | 1.55e-03 | 199 | 7 | 2 | 6790_UP | |
| Drug | Triamcinolone [124-94-7]; Down 200; 10.2uM; MCF7; HT_HG-U133A | 1.55e-03 | 199 | 7 | 2 | 7192_DN | |
| Drug | Telenzepine dihydrochloride [147416-96-4]; Up 200; 9uM; HL60; HT_HG-U133A | 1.55e-03 | 199 | 7 | 2 | 2388_UP | |
| Drug | LY 294002; Down 200; 10uM; PC3; HT_HG-U133A | 1.55e-03 | 199 | 7 | 2 | 1227_DN | |
| Drug | Ethionamide [536-33-4]; Down 200; 24uM; PC3; HT_HG-U133A | 1.55e-03 | 199 | 7 | 2 | 4593_DN | |
| Drug | Ronidazole [7681-76-7]; Up 200; 20uM; HL60; HT_HG-U133A | 1.55e-03 | 199 | 7 | 2 | 6134_UP | |
| Drug | Procainamide hydrochloride [614-39-1]; Down 200; 14.8uM; MCF7; HT_HG-U133A | 1.55e-03 | 199 | 7 | 2 | 2618_DN | |
| Drug | Allantoin [97-59-6]; Down 200; 25.2uM; MCF7; HT_HG-U133A | 1.57e-03 | 200 | 7 | 2 | 5471_DN | |
| Drug | Haloperidol [52-86-8]; Down 200; 10.6uM; HL60; HG-U133A | 1.57e-03 | 200 | 7 | 2 | 2039_DN | |
| Drug | trifluoperazine dihydrochloride; Down 200; 10uM; HL60; HT_HG-U133A | 1.57e-03 | 200 | 7 | 2 | 1165_DN | |
| Disease | urate measurement, bone density | 8.60e-03 | 619 | 7 | 2 | EFO_0003923, EFO_0004531 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| GPPAHLPYHPHVYPP | 466 | O75909 | |
| HYHPPHLFPAFHPPV | 121 | P10071 | |
| TAAPPPPPDYHHHHQ | 121 | Q8IZL2 | |
| GSPAYHLPHPHPHPP | 11 | Q8TDC3 | |
| PPPSHPQRTFYPHHP | 651 | Q5JSZ5 | |
| VPHPHPHPPPYPHFT | 936 | Q14151 | |
| QPPHHPYYQHHAPPP | 616 | Q96MU7 | |
| PYYQHHAPPPQAHPP | 621 | Q96MU7 | |
| HAPPPQAHPPYSGHH | 626 | Q96MU7 |